The Tranquilizer That Replaced Xylazine Makes Withdrawal an ICU Event. Most Drug Tests Can't See It.

Paramedics in Philadelphia started noticing something strange in 2024. They gave a person naloxone, the overdose reversal drug. The person started breathing again. And then they stayed down, unresponsive, as if something else was still holding the door shut. The Philadelphia Inquirer reported that this was the first clue that a second sedative had joined the fentanyl supply.

That sedative was medetomidine. It is a veterinary drug, used to calm animals before procedures, and it is not an opioid, which is why naloxone does nothing to it.

You can’t treat what the test can’t see, and right now the test mostly can’t see it.

Why it’s a different animal than xylazine

If you have been around street fentanyl for the last few years, you know xylazine, the “tranq” that came with the wounds. Medetomidine is a cousin in function and a stranger in practice. Both calm the body by pressing on the same set of receptors, the ones that turn down the nervous system’s alarm. The difference is potency and what happens when you come off it. Medetomidine’s relative, dexmedetomidine, is a drug anesthesiologists already use in intensive care to sedate patients. That fact turned out to matter, because it is also how doctors found a way to treat it.

The reason the withdrawal is dangerous is mechanical. Medetomidine suppresses the body’s adrenaline-driven stress response. Take it away abruptly, after weeks or months of regular exposure, and the response comes back with interest. In Pittsburgh, clinicians described 23 adults at two hospitals between October 2024 and March 2025 with severe autonomic hyperactivity, the medical term for a nervous system stuck in overdrive, after they stopped using illicit opioids. In the 10 patients with confirmed exposure, median peak heart rate was 165 beats a minute and median peak systolic blood pressure was 200. Seven developed metabolic acidosis, a dangerous shift in blood chemistry; three had acute kidney injury and three had heart muscle injury; one went into cardiac arrest or a dangerous rhythm. Opioids and sedatives alone barely helped.

This is not the withdrawal you’ve heard about from the movies, or from your own bad week. It is a body trying to run a marathon while lying in a bed.

What the numbers say, and what they can’t

Philadelphia is where the pattern was clearest. A CDC study of 165 patients at Penn Medicine, Jefferson Health and Temple Health between September 2024 and January 2025 found that 91 percent needed intensive care and 24 percent were intubated, according to the Inquirer. Of the 165, 137 received dexmedetomidine and every one of them improved. Dr. Jeanmarie Perrone of Penn Presbyterian Medical Center said the diagnosis came by elimination. “Ultimately, it was a process of elimination,” she told the Inquirer, and she noted that opioid withdrawal doesn’t normally require an ICU bed and that her hospitals don’t have many to spare.

Two figures show how fast the supply changed. Philadelphia health officials issued a medetomidine alert in May 2024 after just two positive drug-sample tests. By the last four months of 2024, the Inquirer reports, 72 percent of the illicit opioid samples tested in the study contained it. In Chicago in May 2024, a suspected medetomidine-opioid overdose cluster sickened 178 people in a single week.

I want to be careful about what this does not prove. The Philadelphia numbers come from a study of hospitalized patients, which means they describe the people who got sick enough to be admitted, not everyone who used the supply. Other versions of the same cohort have reported different percentages for ICU use and sample size, so treat the exact rates as provisional until the final peer-reviewed figures are settled. The Pittsburgh series is ten confirmed patients, a handful, though a consistent one. The pattern, though, appears across cities.

The Pittsburgh series is ten confirmed patients, a handful, though a consistent one.

The same story, one more time

We know how this goes. In May 2024, Philadelphia health officials issued a medetomidine alert after just two positive drug-sample tests. The same month, a suspected medetomidine-opioid cluster sickened 178 people in a single week in Chicago. By the last four months of 2024, nearly three in four tested samples in the Philadelphia study contained it. By spring 2025, CDC was publishing Notes from the Field out of Pittsburgh, and hospitals were learning the syndrome one ICU bed at a time. A drug appears, a few clinicians see something strange, an alert goes out, and by the time the rest of the system catches up, the supply has already turned over.

Regina LaBelle, the former White House addiction policy official, told STAT in a different context that scheduling past fentanyl analogs did not stop new chemicals from appearing. A dealer needs something cheap to stretch product, and something cheap is always available. What replaced xylazine wasn’t a rule. It was a better margin.

What providers do this week

There is no rapid clinical test for medetomidine. In the Pittsburgh series, the parent drug showed up in only 2 of the 10 patients on full urine drug screening, though its metabolites, the breakdown products, were present in all 10. The authors’ conclusion is the one every clinic should tape to the wall: where medetomidine is in the supply, be ready to manage this withdrawal even when the test is negative.

Practical moves: if a patient who uses illicit opioids presents with racing heart, high blood pressure, shaking and vomiting that standard withdrawal medicine isn’t touching, call it a possible medetomidine withdrawal and escalate. Ask your ED and your inpatient unit whether they have a protocol that includes dexmedetomidine or the alternatives the Pittsburgh team used, such as clonidine, guanfacine and phenobarbital. Check whether your harm reduction partners have medetomidine test strips, which an April 2026 presentation from the training center IRETA says are now available. And add a standing item to your team meeting: what do we do when someone says they can’t go through withdrawal because the last time put them in a hospital.

That last item is the one that keeps people using. You probably know somebody who did this math. If you are the person in the bed, or the one who watched, you have not been weak. Your body was doing something medically dangerous, and the system was not ready.

If you or someone you love is using opioids right now, naloxone does not reverse medetomidine but it does reverse the fentanyl that usually comes with it, and it is still worth carrying. Treatment that includes medical withdrawal management exists in places that can handle this, and SAMHSA’s helpline, 1-800-662-4357, can help you find one. The danger is in doing this alone and fast. It is not in asking.

The people who stand at the edge of this, the paramedics who noticed a patient who wouldn’t wake, the ER doctor who admitted she didn’t have enough beds, are the ones who named it first. They did not need a rule. They needed to be believed, and then they needed the tools.